807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza).

2.50
Hdl Handle:
http://hdl.handle.net/10541/620711
Title:
807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza).
Authors:
Harshman, L; Logue, John P; Sternberg, C; Sundar, S; Schrijvers, D; Schostak, M; Sylvester, J; George, S; Tucci, M; Mantz, C; Borrega, P; Ziem, P; Concepcion, R; Miller, K; Sartor, O; Kalinovsky, J; De Sanctis, Y; Tombal, B
Affiliation:
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston
Citation:
807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza). 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620711
DOI:
10.1093/annonc/mdx370.024
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx370.024/4108893/807PFirst-interim-results-of-the-radium223-Ra223
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHarshman, Len
dc.contributor.authorLogue, John Pen
dc.contributor.authorSternberg, Cen
dc.contributor.authorSundar, Sen
dc.contributor.authorSchrijvers, Den
dc.contributor.authorSchostak, Men
dc.contributor.authorSylvester, Jen
dc.contributor.authorGeorge, Sen
dc.contributor.authorTucci, Men
dc.contributor.authorMantz, Cen
dc.contributor.authorBorrega, Pen
dc.contributor.authorZiem, Pen
dc.contributor.authorConcepcion, Ren
dc.contributor.authorMiller, Ken
dc.contributor.authorSartor, Oen
dc.contributor.authorKalinovsky, Jen
dc.contributor.authorDe Sanctis, Yen
dc.contributor.authorTombal, Ben
dc.date.accessioned2017-12-02T17:38:21Z-
dc.date.available2017-12-02T17:38:21Z-
dc.date.issued2017-09-
dc.identifier.citation807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza). 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx370.024-
dc.identifier.urihttp://hdl.handle.net/10541/620711-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx370.024/4108893/807PFirst-interim-results-of-the-radium223-Ra223en
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Bostonen
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.